Sign in
Canada Source-linked decisions Coverage checked

Canada Case Law

Search judgments by proposition, citation, court, judge or legal topic, then move directly into the source-grounded case analysis.

Courts on this page
3 court collections
Last checked

Canada decisions

Decisions matching the current search

Clear filters
Intellectual property 2024 FC 1849

Bayer Inc. v. Amgen Canada Inc.

The Federal Court held that the 276 Patent was ineligible for listing because Claim 58 did not claim the very change in use approved by the SNDS-related NOC.

  • Pmnoc regulations
  • Patent listing eligibility
  • Claim construction
  • Abbott test
  • Notice of compliance
  • Biosimilar regulatory stay
Read case analysis
Patent law 2024 FC 1848

Serono v. Canada (Health)

The Federal Court held the Minister reasonably listed Serono’s patent on the date it was found eligible, not the submission date, and dismissed the judicial review.

  • Pm(noc) regulations
  • Patent listing date
  • Frozen register
  • Standard of review - reasonableness
  • Cusma obligations
  • Notice of allegation procedure
Read case analysis
Administrative law 2024 FCA 66

Janssen Inc. v. Canada (Attorney General)

The Minister reasonably interpreted and applied subsection C.08.004.1(1) of the Food and Drug Regulations consistent with binding prior Federal Court of Appeal authority; CUSMA does not amend domestic legislation or displace that interpretation; SPRAVATO is not an 'innovative drug' under subsection C.08.004.1(1) and is therefore not entitled to data protection, so the appeal is dismissed.

  • Data protection
  • Innovative drug definition
  • Statutory interpretation
  • Treaty interpretation
  • Vires challenge
Read case analysis
Administrative law 2020 FC 938

Catalyst Pharmaceuticals Inc v. Canada (Attorney General)

Federal Court dismissed an interlocutory stay motion concerning Health Canada’s NOC for Médunik’s Ruzurgi, finding no clear irreparable harm and that convenience favoured the respondents.

  • Data protection under food and drug regulations
  • Notice of compliance (noc)
  • Interlocutory injunction/stay
  • Judicial review
  • Standing
  • Interlocutory-injunction
Read case analysis
Administrative law 2020 FC 397

Glaxosmithkline Biologicals S.A. v. Canada (Health)

The Federal Court set aside Health Canada’s refusal to issue a Certificate of Supplementary Protection for GSK’s SHINGRIX patent and remitted the matter for redetermination.

  • Certificate of supplementary protection
  • Definition of medicinal ingredient
  • Vaccine adjuvants
  • Statutory interpretation
  • Reasonableness review
  • Implementation of ceta
Read case analysis
Administrative law 2017 FC 1023

Galderma Canada Inc v. Canada (Attorney General)

The Federal Court granted judicial review of a PMPRB decision, quashed the Board’s ruling, and held the Board had misapplied the statutory inquiry under s. 79(2).

  • Jurisdiction
  • Procedural fairness
  • Statutory interpretation
  • Scope of patent
  • Judicial review
  • Standard of review
Read case analysis
Administrative law 2017 FC 315

Apotex Inc. v. Canada (Health)

La Cour fédérale a rejeté la demande de contrôle judiciaire d’Apotex, concluant que l’exigence de renseignements supplémentaires sur l’intégrité des données était ni entachée par l’import ban ni déraisonnable.

  • Data integrity
  • Import ban
  • Establishment licence
  • Notice of compliance (noc)
  • Procedural fairness
  • Improper purpose
Read case analysis
Employment law 2016 BCSC 2059

IRIS The Visual Group Western Canada Inc. v. Park

Court held the non-competition covenant unenforceable for overbreadth, dismissed the non-solicitation claim, and found the damages clause to be a penalty.

  • Non-competition clauses
  • Non-solicitation clauses
  • Liquidated damages v. penalty
  • Patient records ownership and transfer
  • Interpretation of restrictive covenants
  • Unconscionability
Read case analysis
Administrative law 2015 FC 959

Photocure ASA v. Canada (Health)

The Federal Court dismissed Photocure’s judicial review, upheld the Minister’s refusal of data protection for CYSVIEW, and excluded the competing expert affidavits.

  • Data protection
  • Innovative drug definition
  • Judicial review
  • Standard of review
  • Admissibility of expert evidence
  • Judicial-review
Read case analysis
Patent law 2015 FC 458

Shire Canada Inc. v. Cobalt Pharmaceuticals Company

The Federal Court dismissed Shire’s motion to strike affidavit evidence and to file reply evidence in a PM(NOC) proceeding, finding no clear error in the prothonotary’s order.

  • Notice of compliance regulations
  • Admissibility of evidence
  • Improper listing
  • Claim construction
  • Standard of review
  • Patent-law
Read case analysis

About this LexChat collection

Canada decisions are organised by court, judge, legal area and indexed issue so a practitioner can move from a proposition to a citable authority with the surrounding context intact.